Loading...
•
Jun 30, 2022
Celldex Q2 2022 Earnings Report
Celldex reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.
Key Takeaways
Celldex reported a net loss of $36.0 million, or ($0.77) per share, for the second quarter of 2022. Total revenue was $0.2 million, and cash, cash equivalents, and marketable securities totaled $356.8 million as of June 30, 2022.
Reported positive interim data from barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria presented at EAACI 2022
Dosed first patients in Phase 2 chronic urticaria studies
Cash, cash equivalents and marketable securities as of June 30, 2022 were $356.8 million
Recorded a one-time loss of $15.0 million in the second quarter of 2022 related to the initial payment due under the Term Sheet entered with SRS
Forward Guidance
Celldex believes that the cash, cash equivalents and marketable securities at June 30, 2022 are sufficient to meet estimated working capital requirements and fund planned operations through 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...